FY 1996 Financial Report
This past fiscal year, which ran from June 1, 1995 to May 31, 1996, was MAPS' tenth and most successful ever in terms of both fund-raising and membership. I believe that at least part of this increasing …
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
Smoked Marijuana for HIV-Associated Anorexia and Wasting Protocol
Smoked Marijuana for HIV-Associated Anorexia and Wasting Protocol, (IND#43,542) submitted to the NIH May 1, 1996 by Dr. Donald Abrams.
Psilocybin’s Effects on Cognition
Investigator: Manfred Spitzer, MD, PhD et al. Psychiatrische Universitats Klinic, Heidelberg, Germany Human clinical study, completed and published. More psilocybin research in Germany Spitzer M, et al. …
A Dose/Response Human Pilot Study – Safety and Efficacy of MDMA in Modification of Physical Pain and Psychological Distress in End-Stage Cancer Patients
[This is not the current version of this protocol] Version 4.1 August 22, 1995 A DOSE/RESPONSE HUMAN PILOT STUDY – SAFETY AND EFFICACY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN MODIFICATION OF PHYSICAL …
FY 1995 Financial Report
You can read this report in its original form here. Total Income for FY 94-95 was $107,184. Total Expenses for FY 94-95 were $133,153. See original report.
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
FDA-Regulated Research and the Effort to Begin It
Dr. Donald Abrams’ FDA-approved research protocol, (IND#43,542) comparing the effectiveness of smoked marijuana and the oral THC capsule in promoting weight gain in patients suffering from the AIDS …
FY 1994 Financial Report
You can read this report in its original form here. Total Income for FY 93-94 was $106,650.48. There you have it, MAPS' financial report for FY 93-94. MAPS continues to grow as does its research agenda, …
Medical Marijuana Clinical Plan
A comprehensive clinical plan developed by MAPS in consultation with the FDA for the investigation of marijuana’s medical use in the treatment of the HIV-related wasting syndrome. This Clinical Plan …
FY 1993 Financial Report
At the beginning of this fiscal year, MAPS had about 350 members and $897 in the bank. By the end of the fiscal year, MAPS' membership had doubled to 707 and its balance was $46,066 (consisting of …
FY 1992 Financial Report
You can read this report in its original form here. MAPS' total income in FY 91-92 was $28,859.55. The following categories had no expenditures this fiscal year. Public Relations/Ads, Salaries, Grants, …